Last reviewed 2026-04-19 · How we verify

Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations

2 treatments

Approved treatments

IMJUDO · ASTRAZENECA AB
Imjudo · AstraZeneca
Tremelimumab-actl binds to CTLA-4, blocking its interaction with CD80 and CD86, thereby enhancing T-cell activation and reducing tumor growth.

Competitive intelligence

For the full treatment-landscape CI brief — marketed leaders side-by-side, pipeline by phase, recent regulatory actions, sponsor landscape:

Frequently asked questions about Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations

What drugs treat Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations?

Tracked treatments include IMJUDO, Imjudo.

What is the treatment for Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations?

Standard treatment for Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations includes IMJUDO, Imjudo. See the treatment landscape page for first-line, second-line and salvage options.

Treatment landscape: Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations patent cliff · Metastatic non-small cell lung cancer with no anaplastic lymphoma kinase genomic tumor aberrations CI report
Treatment: IMJUDO · ASTRAZENECA AB
Treatment: Imjudo · AstraZeneca
All diseases: Browse the disease index · Disease landscape hub

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing